MorphoSys AG
MOR
Cena:
Valuace
85
Růst
15
Zdraví
75
Zprávy
Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
ROYALTY PHARMA ANNOUNCES SALE OF MORPHOSYS DEVELOPMENT FUNDING BONDS
29-01-2025
NEW YORK, JAN. 29, 2025 (GLOBE NEWSWIRE) -- ROYALTY PHARMA PLC (NASDAQ: RPRX) TODAY ANNOUNCED THE CL...
Více zde
MERGER SQUEEZE-OUT OF MORPHOSYS MINORITY SHAREHOLDERS APPROVED AT 2024 ANNUAL GENERAL MEETING
27-08-2024
MUNICH, GERMANY / ACCESSWIRE / AUGUST 27, 2024 / MORPHOSYS AG TODAY ANNOUNCED THAT ITS SHAREHOLDERS ...
Více zde
SHAREHOLDER ALERT: THE M&A CLASS ACTION FIRM INVESTIGATES TENDER OFFER EXPIRING AUGUST 2, 2024, OF MORPHOSYS AG – MOR
16-07-2024
NEW YORK, JULY 16, 2024 (GLOBE NEWSWIRE) -- MONTEVERDE & ASSOCIATES PC (THE “M&A CLASS ACTION FIRM...
Více zde
SHAREHOLDER ALERT: THE M&A CLASS ACTION FIRM INVESTIGATES TENDER OFFER EXPIRING AUGUST 2, 2024, OF MORPHOSYS AG - MOR
15-07-2024
NEW YORK , JULY 15, 2024 /PRNEWSWIRE/ -- MONTEVERDE & ASSOCIATES PC (THE "M&A CLASS ACTION FIRM"), H...
Více zde
MORPHOSYS ANNOUNCES VOLUNTARY DELISTING FROM THE NASDAQ GLOBAL MARKET
12-07-2024
PLANEGG/MUNICH, GERMANY--(BUSINESS WIRE)--MORPHOSYS AG (FSE: MOR; NASDAQ: MOR) TODAY ANNOUNCED THAT ...
Více zde
MOR STOCK ALERT: HALPER SADEH LLC IS INVESTIGATING WHETHER THE SALE OF MORPHOSYS AG IS FAIR TO SHAREHOLDERS
20-06-2024
NEW YORK--(BUSINESS WIRE)--HALPER SADEH LLC, AN INVESTOR RIGHTS LAW FIRM, IS INVESTIGATING WHETHER T...
Více zde
MORPHOSYS AND NOVARTIS SIGN DELISTING AGREEMENT AND INTEND TO IMPLEMENT A MERGER SQUEEZE-OUT OF MORPHOSYS' MINORITY SHAREHOLDERS
20-06-2024
PLANEGG/MUNICH, GERMANY--(BUSINESS WIRE)--MORPHOSYS AG (FSE: MOR; NASDAQ: MOR) TODAY ANNOUNCED THAT ...
Více zde
AD HOC: NOVARTIS BIDCO GERMANY AG INTENDS TO IMPLEMENT A MERGER SQUEEZE-OUT OF MORPHOSYS AG'S MINORITY SHAREHOLDERS
20-06-2024
PLANEGG AND MUNICH, GERMANY / ACCESSWIRE / JUNE 20, 2024 / MORPHOSYS AG (FSE:MOR)(NASDAQ:MOR) ANNOUN...
Více zde
THE STATE OF MASSACHUSETTS ISSUES MOR-EV APPROVAL, GRANTING MULLEN'S CLASS 3 EV TRUCK A $15,000 CASH VOUCHER PER VEHICLE SOLD
11-06-2024
UNDER THE MOR-EV PROGRAM, THE MULLEN THREE EV TRUCK, WITH A SUGGESTED MSRP OF $68,500, NOW QUALIFIES...
Více zde
MORPHOSYS AG REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
29-04-2024
PLANEGG/MUNICH, GERMANY--(BUSINESS WIRE)--MORPHOSYS AG (FSE: MOR; NASDAQ: MOR) REPORTS RESULTS FOR T...
Více zde
MORPHOSYS TO PRESENT NEW PHASE 3 MANIFEST-2 DATA ON PELABRESIB IN MYELOFIBROSIS IN ORAL PRESENTATION AT 2024 ASCO ANNUAL MEETING
24-04-2024
ADDITIONAL ASCO 2024 POSTER PRESENTATION WILL INCLUDE NEW FINDINGS FROM THE PHASE 2 STUDY OF TULMIME...
Více zde
MORPHOSYS' MANAGEMENT BOARD AND SUPERVISORY BOARD RECOMMEND SHAREHOLDERS ACCEPT PUBLIC TAKEOVER OFFER BY NOVARTIS
11-04-2024
NOVARTIS OFFERS € 68.00 PER SHARE IN CASH, REPRESENTING A TOTAL EQUITY VALUE OF € 2.7 BILLION SH...
Více zde
MORPHOSYS' MANAGEMENT BOARD AND SUPERVISORY BOARD RECOMMEND SHAREHOLDERS ACCEPT PUBLIC TAKEOVER OFFER BY NOVARTIS
11-04-2024
PLANEGG/MUNICH, GERMANY--(BUSINESS WIRE)--THE MANAGEMENT BOARD AND SUPERVISORY BOARD OF MORPHOSYS AG...
Více zde
MORPHOSYS ANNOUNCES U.S. ANTITRUST CLEARANCE OF PROPOSED ACQUISITION BY NOVARTIS UNDER HSR ACT
22-03-2024
PLANEGG AND MUNICH, GERMANY / ACCESSWIRE / MARCH 22, 2024 / MORPHOSYS AG (FSE:MOR)(NASDAQ:MOR) TODAY...
Více zde
MORPHOSYS AG REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
13-03-2024
PLANEGG/MUNICH, GERMANY--(BUSINESS WIRE)--MORPHOSYS AG (FSE: MOR; NASDAQ: MOR) REPORTS RESULTS FOR T...
Více zde
INVITATION TO MORPHOSYS' FULL YEAR RESULTS 2023 CONFERENCE CALL ON MARCH 14, 2024
07-03-2024
CONFERENCE CALL ALERT PLANEGG AND MUNICH, GERMANY / ACCESSWIRE / MARCH 7, 2024 / MORPHOSYS AG (FSE:M...
Více zde
MORPHOSYS ENTERS INTO BUSINESS COMBINATION AGREEMENT TO BE ACQUIRED BY NOVARTIS FOR € 2.7 BILLION EQUITY VALUE
05-02-2024
TAFASITAMAB SOLD TO INCYTE NOVARTIS TO LAUNCH A VOLUNTARY PUBLIC TAKEOVER OFFER FOR ALL MORPHOSYS SH...
Více zde
NOVARTIS TO STRENGTHEN ONCOLOGY PIPELINE WITH AGREEMENT TO ACQUIRE MORPHOSYS AG FOR EUR 68 PER SHARE OR AN AGGREGATE OF EUR 2.7BN IN CASH
05-02-2024
BASEL, FEBRUARY 05, 2024 – NOVARTIS TODAY ANNOUNCED THAT IT HAS ENTERED INTO AN AGREEMENT TO MAKE ...
Více zde
MORPHOSYS REPORTS PRELIMINARY 2023 MONJUVI U.S. NET PRODUCT SALES AND GROSS MARGIN, PROVIDES 2024 FINANCIAL GUIDANCE AND REDUCES FINANCIAL LIABILITY
30-01-2024
PRELIMINARY 2023 MONJUVI U.S. NET PRODUCT SALES OF US$ 92.0 MILLION (€ 85.0 MILLION) AND PRELIMINA...
Více zde
MORPHOSYS TO PRESENT AT THE 42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
08-01-2024
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / JANUARY 8, 2024 / MORPHOSYS AG (FSE:MOR)(NASDAQ:MOR) TODAY AN...
Více zde
MORPHOSYS' PELABRESIB IMPROVES ALL FOUR HALLMARKS OF MYELOFIBROSIS IN PHASE 3 MANIFEST-2 STUDY
10-12-2023
PLANEGG/MUNICH, GERMANY--(BUSINESS WIRE)--MORPHOSYS AG (FSE: MOR; NASDAQ: MOR) TODAY ANNOUNCED COMPR...
Více zde
AD HOC: MORPHOSYS' PHASE 3 STUDY OF PELABRESIB IN MYELOFIBROSIS DEMONSTRATES STATISTICALLY SIGNIFICANT IMPROVEMENT IN SPLEEN VOLUME REDUCTION AND STRONG POSITIVE TREND IN SYMPTOM REDUCTION
20-11-2023
PUBLICATION OF AN INSIDE INFORMATION ACCORDING TO ARTICLE 17 PARA. 1 OF THE REGULATION (EU) NO....
Více zde
MORPHOSYS' PHASE 3 STUDY OF PELABRESIB IN MYELOFIBROSIS DEMONSTRATES STATISTICALLY SIGNIFICANT IMPROVEMENT IN SPLEEN VOLUME REDUCTION AND STRONG POSITIVE TREND IN SYMPTOM REDUCTION
20-11-2023
PLANEGG/MUNICH, GERMANY--(BUSINESS WIRE)--MORPHOSYS AG (FSE: MOR; NASDAQ: MOR) TODAY ANNOUNCED STRON...
Více zde
MORPHOSYS AG REPORTS FIRST NINE MONTHS AND THIRD QUARTER 2023 FINANCIAL RESULTS
15-11-2023
PLANEGG/MUNICH, GERMANY--(BUSINESS WIRE)--MORPHOSYS AG (FSE: MOR; NASDAQ: MOR) REPORTS RESULTS FOR T...
Více zde
INVITATION TO MORPHOSYS' THIRD QUARTER AND FIRST NINE MONTHS 2023 FINANCIAL RESULTS CONFERENCE CALL ON NOVEMBER 16, 2023
09-11-2023
CONFERENCE CALL ALERT PLANEGG AND MUNICH, GERMANY / ACCESSWIRE / NOVEMBER 9, 2023 / MORPHOSYS AG (FS...
Více zde
MORPHOSYS TO SHOWCASE PHASE 3 MANIFEST-2 DATA ON PELABRESIB IN MYELOFIBROSIS IN ORAL PRESENTATION AT 2023 ASH ANNUAL MEETING
02-11-2023
FOLLOWING TOPLINE RESULTS EXPECTED IN THE COMING WEEKS, THE ORAL SESSION AT ASH 2023 IN DECEMBER WIL...
Více zde
MORPHOSYS REPORTS PRELIMINARY Q3 2023 MONJUVI U.S. SALES AND GROSS MARGIN, AND UPDATES FINANCIAL GUIDANCE FOR 2023
25-10-2023
PRELIMINARY Q3 2023 MONJUVI U.S. NET PRODUCT SALES OF US$ 23.4 MILLION (€ 21.5 MILLION) PRELIMINAR...
Více zde
MORPHOSYS RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR TULMIMETOSTAT IN ENDOMETRIAL CANCER
12-09-2023
TULMIMETOSTAT FOLLOWS PELABRESIB (2018) AND TAFASITAMAB (2014) AS THE COMPANY'S THIRD CLINICAL PROGR...
Více zde
INVITATION TO MORPHOSYS' FIRST QUARTER 2023 FINANCIAL RESULTS CONFERENCE CALL ON MAY 4, 2023
27-04-2023
CONFERENCE CALL ALERT MUNICH, GERMANY / ACCESSWIRE / APRIL 27, 2023 / MORPHOSYS AG (FSE:MOR)(NASDAQ:...
Více zde
INVITATION TO MORPHOSYS' FULL YEAR RESULTS 2022 CONFERENCE CALL ON MARCH 16, 2023
09-03-2023
CONFERENCE CALL ALERT PLANEGG AND MUNICH, GERMANY / ACCESSWIRE / MARCH 9, 2023 / MORPHOSYS AG (FSE:M...
Více zde
Dokumenty nejsou k dispozici
